Juvenile spondyloarthropathies (JSpA) encompass a cluster of interconnected rheumatic conditions that manifest during the formative stages of an individual’s life, specifically prior to their sixteenth birthday. The primary characteristics of juvenile spondyloarthropathies include both axial and peripheral arthritis, enthesitis, extra-articular symptoms, and a strong association with the human leukocyte antigen HLA-B27. There exists substantial evidence of the involvement of tumor necrosis factor and interleukin-17 in the pathophysiology of these conditions. A variety of non-biological and biological therapies have been employed in the treatment of these intricate
disorders, showing inconsistent outcomes.
This study examines the correlation between HLA-B27 and juvenile spondyloarthropathies, as well as the involvement of HLA-B27 in the pathology of the disease. The present study focuses on the clinical characteristics of HLA-B27 in juvenile spondyloarthropathies and examines the recently recommended therapy for individuals with juvenile spondyloarthropathies.
Hi! I can explain how to publish or share, find articles in your field, format citations and answer questions about fees and licensing. How can I help?
Answers are based on The Gufo’s published policies. Editorial decisions are made by the editorial team.
